Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Equity Ratio (2020 - 2023)

Historic Equity Ratio for Cullinan Therapeutics (CGEM) over the last 4 years, with Q3 2023 value amounting to 0.95.

  • Cullinan Therapeutics' Equity Ratio fell 20.36% to 0.95 in Q3 2023 from the same period last year, while for Sep 2023 it was 0.95, marking a year-over-year decrease of 20.36%. This contributed to the annual value of 0.95 for FY2022, which is 200.18% down from last year.
  • Latest data reveals that Cullinan Therapeutics reported Equity Ratio of 0.95 as of Q3 2023, which was down 20.36% from 0.96 recorded in Q2 2023.
  • Cullinan Therapeutics' 5-year Equity Ratio high stood at 0.99 for Q2 2021, and its period low was 0.91 during Q2 2022.
  • For the 4-year period, Cullinan Therapeutics' Equity Ratio averaged around 0.96, with its median value being 0.96 (2022).
  • Its Equity Ratio has fluctuated over the past 5 years, first tumbled by 823.77% in 2022, then skyrocketed by 562.08% in 2023.
  • Quarter analysis of 4 years shows Cullinan Therapeutics' Equity Ratio stood at 0.93 in 2020, then rose by 4.29% to 0.97 in 2021, then dropped by 2.0% to 0.95 in 2022, then dropped by 0.61% to 0.95 in 2023.
  • Its Equity Ratio stands at 0.95 for Q3 2023, versus 0.96 for Q2 2023 and 0.94 for Q1 2023.